A Phase 3 interventional study of Tapinarof cream, 1% in Atopic Dermatitis, sponsored by Organon and Co. Completed at 112 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 8th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 728 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 168 across the 12 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 5 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
14 studies in Dermatitis, Atopic by Organon & Co.: none open now, 1 under way, 1 of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 14 studies in Dermatitis, Atopic by Organon & Co., this one has the largest enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 12th registered.
Organon & Co.’s Dermatitis, Atopic studies by the year they started, since 2003.
1 of the studies testing tapinarof in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, from their registry updates:
Among Organon & Co.’s 14 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
At the completion of the Week 8 visit of study DMVT-505-3101 (NCT05014568) or study DMVT-505-3102 (NCT05032859) or the Day 28 visit of study DMVT-505-2104 (NCT05186805) (Day 1 [Baseline] in this study), all eligible subjects will be offered enrollment in this open-label long-term extension (OL-LTE) study. Approximately 125 additional pediatric subjects ages 2 to \< 18 years who are not eligible for participation in the Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) will be enrolled directly into this OL-LTE study. Study visits during the treatment period for all subjects will occur every 4 weeks (± 3 days). The total duration of study participation will be approximately 48 weeks for rollover subjects (Baseline to Final Visit) with a 1-week Safety Follow-up Period and approximately 52 weeks for direct-enrolling subjects (Screening to Final Visit) with a 1-week Safety Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Roll-over Subjects Only:
For Direct-Enrolling Subjects Only:
For All Subjects:
Exclusion Criteria:
For Rollover Subjects Only:
For Direct-Enrolling Subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects entering with vIGA-AD (Validated Investigator Global Assessment of Atopic Dermatitis) ≥1 receive treatment with study drug until they achieve vIGA-AD=0, at which time treatment is discontinued and subjects are monitored for durability of response (remittive response). If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved. Subjects entering with a vIGA-AD=0 discontinue treatment and are monitored for duration of remittive response. If/when disease worsening occurs (vIGA-AD ≥2), treatment is re-initiated and continued until vIGA-AD =0 is achieved. This treatment and re-treatment pattern of use continue until the end of the study.
Drug: Tapinarof cream, 1%
Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events
For rollover subjects, all AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug will be considered a TEAE.
Time frame: Baseline to Week 49
Frequency of Adverse Events and Serious Adverse Events
All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE.
Time frame: Baseline to Week 49
Change From Baseline in Clinical Laboratory Values (g/L)
The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (U/L)
The mean chemistry parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (mmol/L)
The mean chemistry parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (Umol/L)
The mean chemistry parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (10^9 Cells/L)
The mean hematology parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (%)
The mean hematology parameters were assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (L/L)
The hematology parameter, Hematocrit, was assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (pg)
The hematology parameter, Ery. Mean Corpuscular Hemoglobin was assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (fl)
The hematology parameter, Ery. Mean Corpuscular Volume, was assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Change From Baseline in Clinical Laboratory Values (10^12 Cells/L)
The hematology parameter, Erythrocytes, was assessed for changes and trends over the course of the study.
Time frame: Baseline to Week 48
Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear )
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.
Time frame: Baseline to Week 48
Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild)
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.
Time frame: Baseline to Week 48
Absolute Change From Baseline in %BSA Affected
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
Time frame: Baseline to Week 48
Percent Change From Baseline in %BSA Affected
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
Time frame: Baseline to Week 48
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Week 48
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Week 48
Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Week 48
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Week 48
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48.
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
Time frame: Baseline to Week 48
Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.
Time frame: Baseline to Week 48
Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.
Time frame: Baseline to Week 48
Change From Baseline in Vital Signs - Pulse
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
Time frame: Baseline to Week 48
Change From Baseline in Vital Signs - Blood Pressure (Systolic and Diastolic)
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
Time frame: Baseline to Week 48
Change From Baseline in Vital Signs - Temperature
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
Time frame: Baseline to Week 48
| Milestone | Tapinarof Cream |
|---|---|
| Started | 728 |
| Completed | 497 |
| Not completed | 231 |
For rollover subjects, all AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug will be considered a TEAE.
| Participants | Tapinarof Cream |
|---|---|
| Any treatment-emergent AE | 451 |
| Serious treatment-emergent AE | 34 |
All AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. Subjects could have reported more than one TEAE.
| Events | Tapinarof Cream |
|---|---|
| Treatment-emergent AE | 1226 |
| Serious treatment-emergent AE | 45 |
The mean chemistry and hematology parameters were assessed for changes and trends over the course of the study.
| g/L | Tapinarof Cream |
|---|---|
| Albumin (g/L) | -0.5 ± 2.43 |
| Protein (g/L) | 0.0 ± 3.95 |
| Hemoglobin (g/L) | 1.7 ± 8.45 |
| Ery. Mean Corpuscular HGB Concentration (g/L) | 0.0 ± 7.61 |
The mean chemistry parameters were assessed for changes and trends over the course of the study.
| U/L | Tapinarof Cream |
|---|---|
| Alkaline Phosphatase (U/L) | -14.9 ± 69.45 |
| Alanine Aminotransferase (U/L) | -1.5 ± 11.96 |
| Aspartate Aminotransferase (U/L) | -2.6 ± 16.13 |
The mean chemistry parameters were assessed for changes and trends over the course of the study.
| mmol/L | Tapinarof Cream |
|---|---|
| Bicarbonate (mmol/L) | -0.2 ± 2.31 |
| Blood Urea Nitrogen (mmol/L) | 0.04 ± 1.428 |
| Calcium (mmol/L) | -0.019 ± 0.0926 |
| Chloride (mmol/L) | -0.3 ± 2.43 |
| Glucose (mmol/L) | 0.13 ± 1.462 |
| Potassium (mmol/L) | -0.03 ± 0.493 |
| Sodium (mmol/L) | -0.1 ± 2.14 |
The mean chemistry parameters were assessed for changes and trends over the course of the study.
| umol/L | Tapinarof Cream |
|---|---|
| Bilirubin (umol/L) | 0.40 ± 3.434 |
| Enzymatic Creatinine (umol/L) | 2.1 ± 7.92 |
| Creatinine (Jaffe) (umol/L) | 2.7 ± 12.06 |
| Urate (umol/L) | 0.9 ± 52.32 |
The mean hematology parameters were assessed for changes and trends over the course of the study.
| 10^9 cells/L | Tapinarof Cream |
|---|---|
| Basophils (10^9/L) | 0.01 ± 0.051 |
| Eosinophils (10^9/L) | -.03 ± 0.308 |
| Lymphocytes (10^9/L) | -0.02 ± 0.909 |
| Monocytes (10^9/L) | 0.00 ± 0.192 |
| Neutrophils (10^9/L) | 0.22 ± 2.079 |
| Platelets (10^9/L) | -4.0 ± 59.57 |
| Leukocytes (10^9/L) | 0.18 ± 2.474 |
The mean hematology parameters were assessed for changes and trends over the course of the study.
| % of cells | Tapinarof Cream |
|---|---|
| Basophils/Total Cells (%) | 0.03 ± 0.272 |
| Eosinophils/Total Cells (%) | -0.39 ± 3.427 |
| Lymphocytes/Total Cells (%) | -0.73 ± 10.440 |
| Monocytes/Total Cells (%) | -0.09 ± 2.592 |
| Neutrophils/Total Cells (%) | 1.18 ± 11.436 |
| Reticulocytes/Erythrocytes (%) | -0.06 ± 0.402 |
The hematology parameter, Hematocrit, was assessed for changes and trends over the course of the study.
| L/L | Tapinarof Cream |
|---|---|
| Change From Baseline in Clinical Laboratory Values (L/L) | 0.005 ± 0.0263 |
The hematology parameter, Ery. Mean Corpuscular Hemoglobin was assessed for changes and trends over the course of the study.
| pg | Tapinarof Cream |
|---|---|
| Change From Baseline in Clinical Laboratory Values (pg) | 0.13 ± 0.823 |
The hematology parameter, Ery. Mean Corpuscular Volume, was assessed for changes and trends over the course of the study.
| fl | Tapinarof Cream |
|---|---|
| Change From Baseline in Clinical Laboratory Values (fl) | 0.37 ± 2.364 |
The hematology parameter, Erythrocytes, was assessed for changes and trends over the course of the study.
| 10^12 cells/L | Tapinarof Cream |
|---|---|
| Change From Baseline in Clinical Laboratory Values (10^12 Cells/L) | 0.038 ± 0.2905 |
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Complete Disease Clearance During LTE: Number of Subjects Achieving Disease Clearance vIGA-AD =0 (Clear) While on Therapy for Subjects Entered LTE vIGA-AD ≥ 1 (Almost Clear ) | 320 |
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint. It is a static 5-point (0-4) morphological assessment of overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. Higher vIGA-AD scores represents more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Response During LTE: Number of Subjects Achieving vIGA-AD =0 or 1 (Clear or Almost Clear) While on Therapy for Subjects Who Entered LTE With vIGA-AD ≥ 2 (Mild) | 347 |
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
| percentage of BSA | Tapinarof Cream |
|---|---|
| Absolute Change From Baseline in %BSA Affected | -7.14 ± 12.881 |
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in %BSA affected in all subjects, including those on and those off therapy. Assessment of BSA with Atopic Dermatitis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. Lesions on the scalp will not be included in the calculation of %BSA affected. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
| percent change from baseline in % total | Tapinarof Cream |
|---|---|
| Percent Change From Baseline in %BSA Affected | -37.45 ± 189.905 |
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
| Units on a scale | Tapinarof Cream |
|---|---|
| Mean Change From Baseline in Eczema Area and Severity Index (EASI) Score | -4.19 ± 7.248 |
Subjects received treatment with tapinarof intermittently guided by disease severity. This outcome measure assesses the % change from baseline in EASI score in all subjects, including those on and those off therapy. The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
| Units on a scale | Tapinarof Cream |
|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score | -33.70 ± 139.557 |
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. Higher EASI scores indicate more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Percent of Subjects With ≥ 50% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. | 325 |
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. | 256 |
The EASI scoring system is a clinical tool that quantifies the severity of a subject's AD based on both lesion severity and %BSA affected. The EASI is a composite score ranging from 0 to 72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. Higher EASI scores indicate more severe disease.
| Participants | Tapinarof Cream |
|---|---|
| Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline at Week 48. | 178 |
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.
| Units on a scale | Tapinarof Cream |
|---|---|
| Mean Change in Peak Pruritis-Numeric Rating Scale (PP-NRS) From Baseline | -1.618 ± 2.7756 |
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject or caregiver will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week.
| Participants | Tapinarof Cream |
|---|---|
| Number of Subjects With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the PP-NRS From Baseline | 94 |
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
| beats per minute (bpm) | Tapinarof Cream |
|---|---|
| Change From Baseline in Vital Signs - Pulse | -0.9 ± 12.61 |
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
| mmHg | Tapinarof Cream |
|---|---|
| Systolic Blood Pressure (mmHg) | 1.0 ± 10.72 |
| Diastolic Blood Pressure (mmHg) | 0.7 ± 9.78 |
The mean vital sign parameters were assessed for changes and trends over the course of the study. Shifts from Baseline in vital sign parameters were assessed for clinical relevance.
| degrees C | Tapinarof Cream |
|---|---|
| Change From Baseline in Vital Signs - Temperature | 0.02 ± 0.437 |
Collected over For rollover subjects, all AEs reported in this extension study, through study completion, up to 48 weeks, were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug and through study completion, up to 48 weeks, will be considered a TEAE.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Continuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score | 0/728 (0%) | 34/728 (4.7%) | 451/728 (62%) |
| Event | Continuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score |
|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 19/728 |
| PneumoniaInfections and infestations | 5/728 |
| Status asthmaticusRespiratory, thoracic and mediastinal disorders | 3/728 |
| Anaphylactic reactionImmune system disorders | 2/728 |
| HypothyroidismEndocrine disorders | 1/728 |
| AppendicitisInfections and infestations | 1/728 |
| Pneumonia respiratory syncytial viralInfections and infestations | 1/728 |
| Postoperative abscessInfections and infestations | 1/728 |
| Respiratory syncytial virus infectionInfections and infestations | 1/728 |
| Humerus fractureInjury, poisoning and procedural complications | 1/728 |
| Event | Continuous or Intermittent Use of Tapinarof Cream (DMVT-505) Cream According to vIGA-AD Score |
|---|---|
| FolliculitisInfections and infestations | 88/728 |
| NasopharyngitisInfections and infestations | 50/728 |
| Upper respiratory tract infectionInfections and infestations | 50/728 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 44/728 |
| COVID-19Infections and infestations | 42/728 |
| InfluenzaInfections and infestations | 27/728 |
| HeadacheNervous system disorders | 25/728 |
| CoughRespiratory, thoracic and mediastinal disorders | 24/728 |
| ImpetigoInfections and infestations | 22/728 |
| Pharyngitis streptococcalInfections and infestations | 21/728 |
ITT Population
| Age, Continuous(years) | Tapinarof Cream |
|---|---|
| Mean | 15.0 ± 15.32 |
| Age, Customized(Participants) | Tapinarof Cream |
|---|---|
| 2-6 years | 194 |
| 7-11 years | 197 |
| 12-17 years | 213 |
| ≥18 years | 124 |
| Sex: Female, Male(Participants) | Tapinarof Cream |
|---|---|
| Female | 389 |
| Male | 339 |
| Ethnicity (NIH/OMB)(Participants) | Tapinarof Cream |
|---|---|
| Hispanic or Latino | 163 |
| Not Hispanic or Latino | 562 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Tapinarof Cream |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 81 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 219 |
| White | 383 |
| More than one race | 27 |
| Unknown or Not Reported | 13 |
| Region of Enrollment(Count of participants) | Tapinarof Cream |
|---|---|
| Canada | 112 |
| United States | 616 |
| Validated Investigator Global Assessment for Atopic Dermatitis(Participants) | Tapinarof Cream |
|---|---|
| 0 - clear | 58 |
| 1 - almost clear | 189 |
| 2 - mild | 268 |
| 3 - moderate | 182 |
| 4 - severe | 31 |
| Percent Body Surface Area (BSA)(Affected Body Surface Area percentage) | Tapinarof Cream |
|---|---|
| Mean | 10.62 ± 14.259 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 112 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Feb 2024, 28 months.
Results were first posted in Aug 2025, 1 year 5 months after primary completion. A results delay was requested in Apr 2024.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof